Search research articles
Contact Us
Filters
Showing results (161-170 of 210) with videos related to
Page
of 21
Sort By:
Journal of the National Cancer Institute
|
August 12, 2025
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients
Matteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, et al.
Journal of the National Cancer Institute
|
May 15, 2023
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor
Antoinette R Tan, Xiaowei Yang, Stephen M Hewitt, et al.
International Journal of Cancer
|
June 21, 2025
Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials
Bradley D Menz, Natansh D Modi, Ahmad Y Abuhelwa, et al.
JAMA Oncology
|
November 5, 2016
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial
Patrick G Gavin, Nan Song, S Rim Kim, et al.
The New England Journal of Medicine
|
June 4, 2010
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer
Sandra M Swain, Jong-Hyeon Jeong, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2011
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial
Patricia A Ganz, Stephanie R Land, Charles E Geyer, et al.
JNCI Cancer Spectrum
|
November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2024
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Clinical Breast Cancer
|
October 4, 2016
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5
John W Smith, Marc E Buyse, Priya Rastogi, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 210) with videos related to
Sort By:
Page
of 21
Journal of the National Cancer Institute
|
August 12, 2025
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients
Matteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, et al.
Journal of the National Cancer Institute
|
May 15, 2023
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor
Antoinette R Tan, Xiaowei Yang, Stephen M Hewitt, et al.
International Journal of Cancer
|
June 21, 2025
Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials
Bradley D Menz, Natansh D Modi, Ahmad Y Abuhelwa, et al.
JAMA Oncology
|
November 5, 2016
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial
Patrick G Gavin, Nan Song, S Rim Kim, et al.
The New England Journal of Medicine
|
June 4, 2010
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer
Sandra M Swain, Jong-Hyeon Jeong, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2011
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial
Patricia A Ganz, Stephanie R Land, Charles E Geyer, et al.
JNCI Cancer Spectrum
|
November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2024
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Clinical Breast Cancer
|
October 4, 2016
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5
John W Smith, Marc E Buyse, Priya Rastogi, et al.
Page
of 21